ClinicalTrials.gov
public full text
Public Domain
Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study
In this multicenter retrospective cohort study the aim is to determine the safety of omission of axillary lymph node dissection in patients with TNBC and HER2+ tumors with residual macrometastases (in the SLN/TAD/TAS or MARI node) after NAC.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Targeted Axillary Dissection After Neo-adjuvant Chemotherapy#1279427
- Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy in Breast Cancer#1228568
- RISAS Procedure in Node Positive Breast Cancer Following NAC#1228161
- Medico-economic Study of Three Strategies of Sentinel Lymph Node Analysis in Operable Breast Cancer#1161704
- Axillary Management After Neoadjuvant Chemotherapy#968892
Record · ID 1213140
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive